Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Compugen Ltd. manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action, which is assigned to 1 distinct examiner. This indicates a concentrated prosecution effort, where the company's current success at the patent office is tied to the active application. The focus on the examiner suggests that the company is prioritizing a specific technical path at this stage.
The prosecution is occurring within 1 distinct art unit, suggesting a specific technical focus for the company's intellectual property. HALVORSON, MARK is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. Because this 1 examiner is handling the only active matter, the prosecution strategy must be closely aligned with the specific preferences and examination history of the assigned official. For a practitioner, this lack of distribution across different art units or examiners simplifies administrative oversight but increases the impact of the individual's decisions. The alignment of the pending office action with the workload in the Biotechnology & Pharmaceuticals sector highlights a streamlined approach to securing patent rights at this time.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249957 | PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT | AEDER, SEAN E | 46d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249957 | PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT | AEDER, SEAN E | 46d overdue |
| 18452985 | ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF | HALVORSON, MARK | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18452985 | ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF | HALVORSON, MARK | 1646 | §102Other | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18249957 | PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT | AEDER, SEAN E | 1642 | §101§103§112Other | Non-Final OA | 46d overdue | Pending | Apr 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial